The PPARγ agonists rosiglitazone, pioglitazone,troglitazone, and ciglitazone all showed a dose-dependent antiproliferativeeffect on all melanoma cell lines tested at concentrations of 30 μM or higher.This antiproliferative effect was due to a mechanism independent fromapoptosis, which was shown by assessment of the nuclear morphology or bymolecular analysis of DNA fragmentation. The gene discussed is PPARG; the disease is melanoma.